Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

N.C. botanical consortium gets $100K

This article was originally published in The Tan Sheet

Executive Summary

The North Carolina Biotechnology Center awards a $100,000 grant to the Bent Creek Center of Innovation for Natural Biotechnology "to jump-start growth in the natural biotechnology sector," the grantor announces Aug. 14. Annice Brown, an assistant director in the Asheville office of the North Carolina Small Business and Technology Development Center, will coordinate the planning process for the Bent Creek Center. Gaia Herbs, Targacept and the N.C. Natural Products Association support the project, according to the Biotechnology Center. The Bent Creek program will establish an organizational structure and create a business plan, which, upon approval by the Biotechnology Center, will trigger a four-year grant for $2.5 million

You may also be interested in...



Biogen’s Big Day Arrives, But Aducanumab Results Don’t Answer Key Question

Biogen presented highly anticipated data in Alzheimer’s disease at CTAD for its Phase III EMERGE and ENGAGE studies, but one major question remains unanswered: will the FDA approve the drug? 

Biogen’s Big Day Arrives, But Aducanumab Results Don’t Answer Key Question

Biogen presented highly anticipated data in Alzheimer’s disease at CTAD for its Phase III EMERGE and ENGAGE studies, but one major question remains unanswered: will the FDA approve the drug? 

Sage Still Sees Approval Path After Depression Drug Fails In Phase III Trial

Sage Therapeutics points to patient compliance and selection as factors in its failed trial of SAGE-217. The company sees positive implications in the data as it waits for other SAGE-217 studies. 

Topics

UsernamePublicRestriction

Register

PS102079

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel